Evotec AG has received a milestone in its research alliance with Boehringer Ingelheim, triggering a payment of $5.3 million to Evotec. The milestone was for the transition of a respiratory program into preclinical development. Dr. Mario Polywka, Evotec’s chief operating officer, commented, “This is the 16th milestone achieved as part of our alliance with Boehringer Ingelheim and represents an important transition of this program into preclinical development. The alliance continues t...